Published online Aug 16, 2018. doi: 10.12998/wjcc.v6.i8.183
Peer-review started: February 2, 2018
First decision: March 7, 2018
Revised: March 29, 2018
Accepted: June 7, 2018
Article in press: June 8, 2018
Published online: August 16, 2018
Hepatitis B virus (HBV) is one of the most severe human pathogens. It is reported that 240 million individuals globally are chronically infected with HBV and current antivirals cannot clear the infection or adequately suppress disease.
Despite improvement in global access to vaccination and treatment, mortality levels remain high. Chronic hepatitis B can be effectively and safely treated but a cure remains elusive.
The aim of this study is to inhibit HBV DNA expression with anti-gene locked nucleic acid (LNA) in transgenic mice.
The aim of this study was to design liposome based transport of a LNA modified oligonucleotide to inhibit HBV DNA express in transgenic mice, the final objective was to assess the antiviral effects of HBV S gene-specific anti-gene LNA in transgenic mice.
Average rate reductions of HBsAg, HBV DNA, mRNA levels of the HBV S gene and the rate of HBsAg positive liver cells, with statistically significant differences compared with pre-treatment and control values (P < 0.05 for all). Liver and kidney function, and histology showed no abnormalities.
Anti-gene-LNA transacted by cationic liposomes can effectively enter nucleolus in the liver of transgenic mice after tail vein injection and play a role in reducing HBV DNA replication and transcription.
Based on the data presented herein highlight the usefulness of anti-gene-LNA mediated silencing HBV DNA replication and transcription bring forth innovative ideas and potentially viable tool for gene therapy.